



Accredited by
Joint Commission International

A. K. SINGHAL

Vice President
Cum Company Secretary

Indraprastha Medical Corporation Limited

Regd. Office : Sarita Vihar, Delhi-Mathura Road, New Delhi - 110 076. (INDIA)

Corporate Identity Number : L24232DL 1988PLC030958

Phone : 26925801, 26925858 Fax : 91-11-26825601

E-mail : asinghal@apollohospitals.com Website : apollohospdelhi.com



Ref: IMCL/CS/BM/2018

30th January, 2019

The Manager
Listing Department
BSE Limited Phiroze Jeejeebhoy
Towers Dalal Street, Mumbai,
Maharashtra - 400001
Scrip Code: 532150

The Manager
Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra East,
Mumbai, Maharashtra - 400051
Symbol: INDRAMEDCO

Sub.: Unaudited Financial Results for the Quarter and nine months ended 31st December, 2018

Dear Sir,

Enclosed please find a copy of the Unaudited Financial Results for the quarter and nine months ended 31st December, 2018, along with a copy of the Limited Review Report by the Auditors.

The Board meeting started at 03:00 p.m. and ended at 04.40 p.m.

This is for your information and record.

Thanking You,

Sincerely Yours,


A.K.SINGHAL

Encl. as above

INDRAPRASTHA MEDICAL CORPORATION LIMITED
Registered office : Sarita Vihar, Delhi Mathura Road, New Delhi - 110076
Corporate Identity Number : L24232DL1988PLC030958
Phone: 91-11-26925858, 26925801, Fax: 91-11-26823629
E-mail: imcl@apollohospitals.com, Website: apollohospdelhi.com

Statement of Unaudited Financial Results for the Quarter and Nine months ended 31st December, 2018

S. No.	Particulars	Amount (Rs. in Lacs)					
		Quarter ended			Nine months ended		Financial Year ended
		31.12.2018 (Unaudited)	30.09.2018 (Unaudited)	31.12.2017 (Unaudited)	31.12.2018 (Unaudited)	31.12.2017 (Unaudited)	31.03.2018 (Audited)
1	Revenue from operations	19819.73	20017.35	18575.35	58774.94	56270.81	75266.04
2	Other Income	8.49	8.01	54.06	24.20	72.59	80.21
3	Total income	19828.22	20025.36	18629.41	58799.14	56343.40	75346.25
4	Expenses						
	a) Cost of material consumed	3559.97	3647.67	3359.90	10780.48	10578.56	13984.14
	b) Employee benefits expense	5152.93	5006.13	4889.16	14929.70	14343.22	19401.37
	c) Consultation fee paid to Doctors	4955.46	5036.84	4741.47	14873.88	14644.22	19376.42
	d) Finance cost	182.36	173.20	239.89	533.98	682.37	889.94
	e) Depreciation and amortisation expense	747.31	755.78	773.14	2257.61	2309.32	3068.18
	f) Other expenses	4116.09	4183.36	3789.83	12061.46	11407.63	15225.68
	Total expenses	18714.12	18802.98	17793.39	55437.11	53965.32	71945.73
5	Profit before exceptional items and tax	1114.10	1222.38	836.02	3362.03	2378.08	3400.52
6	Exceptional items	-	-	-	-	-	-
7	Profit before tax (PBT)	1114.10	1222.38	836.02	3362.03	2378.08	3400.52
8	Tax expense						
	Current tax	394.61	558.01	174.60	1432.41	783.94	1393.07
	Deferred tax	7.63	(102.88)	109.71	(197.99)	42.05	(102.88)
9	Profit for the period after tax (PAT)	711.86	767.25	551.71	2127.61	1552.09	2110.33
10	Other comprehensive income						
	a). (i) Items that will not be reclassified to profit or loss	(80.04)	(17.24)	45.00	(61.25)	76.55	37.27
	(ii) Income Tax relating to items that will not be reclassified to profit or loss	27.97	6.02	(15.57)	21.40	(26.49)	(13.02)
	Total other comprehensive income, Net of tax expenses	(52.07)	(11.22)	29.43	(39.85)	50.06	24.25
11	Total comprehensive income for the period	659.79	756.03	581.14	2087.76	1602.15	2134.58
12	Paid-up equity share capital (Face value Rs. 10/- each)	9167.30	9167.30	9167.30	9167.30	9167.30	9167.30
13	Earnings per share Basic and Diluted (Rs.)	0.78	0.84	0.60	2.32	1.69	2.30

Notes:

- The above financial results were reviewed by the Audit Committee and have been approved by the Board of Directors at its meeting held on 30th January, 2019.
- The Company operates in a single segment i.e. Healthcare and hence, does not have any additional disclosures to be made under Ind AS 108 on Operating Segments.
- The Statutory Auditors have carried out a Limited review of the financial results for the quarter and nine months ended 31st December, 2018.
- Previous year/period figures have been regrouped / rearranged wherever necessary.

Place : New Delhi
Date : 30th January, 2019



A. Bajpai
Ashok Bajpai
Managing Director

Limited Review Report

To The Board of Directors of Indraprastha Medical Corporation Limited

We have reviewed the accompanying statement of unaudited financial results of **Indraprastha Medical Corporation Limited** ("the Company") for the quarter ended December 31, 2018 and the year to-date results for the period April 01, 2018 to December 31, 2018 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular dated 5 July 2016.

The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2015, other accounting principles generally accepted in India and SEBI Circular dated 5 July 2016 is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in the applicable accounting standards i.e. Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular dated 5 July 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **S.N. Dhawan & Co LLP**
Chartered Accountants
Firm Registration No.: 000050N/N500045



Rajeev K Saxena
Partner
Membership No.: 077974
New Delhi,
January 30, 2019